

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI753776

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
INHIBRX BIOSCIENCES, INC.		01/13/2025
RECEIVING PARTY DATA		
Company Name:	OXFORD FINANCE LLC	
Street Address:	115 South Union Street, Suite 300	
City:	Alexandria	
State/Country:	VIRGINIA	
Postal Code:	22314	
Company Name:	OXFORD FINANCE LLC	
Street Address:	115 South Union Street, Suite 300	
City:	Alexandria	
State/Country:	VIRGINIA	
Postal Code:	22314	
PROPERTY NUMBERS Total: 62		
Property Type	Number	
Application Number:	16601825	
Application Number:	15404016	
Application Number:	18067484	
Application Number:	18956693	
Application Number:	17283830	
Application Number:	16864478	
Application Number:	17816540	
Application Number:	17795500	
Application Number:	15951137	
Application Number:	18520308	
Application Number:	18206354	
Application Number:	16520293	
Application Number:	18969101	
Application Number:	16864480	
Application Number:	18067504	

Property Type	Number
Application Number:	18792984
Application Number:	17608743
Application Number:	13761087
Application Number:	14700105
Application Number:	18451025
Application Number:	18578133
Application Number:	18578137
Application Number:	16864481
Application Number:	18748655
Application Number:	17608738
Application Number:	17922569
Application Number:	17283903
Application Number:	15213296
Application Number:	16387754
Application Number:	17394900
Application Number:	18626699
Application Number:	18264475
Application Number:	18853278
Application Number:	18865854
Application Number:	15003234
Application Number:	18807532
Application Number:	18871526
Application Number:	15217754
Application Number:	18861746
Application Number:	18792921
Application Number:	17418458
Application Number:	18002613
Application Number:	18685665
Application Number:	18685666
Application Number:	16295332
Application Number:	17398851
Application Number:	16538216
Application Number:	17818106
Application Number:	18658421
Application Number:	16600298
Application Number:	17524016
Application Number:	18589536
Application Number:	18923531

Property Type	Number
Application Number:	18726347
Application Number:	18726350
Application Number:	15144470
Application Number:	16419677
Application Number:	16119950
Application Number:	17283902
PCT Number:	US2437846
PCT Number:	US2373279
PCT Number:	US2416505

CORRESPONDENCE DATA

Fax Number: 6173106001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (617)310-5234

Email: prezase@gtlaw.com,kobrenskij@gtlaw.com

Correspondent Name: Eugenia A. Prezas

Address Line 1: c/o Greenberg Traurig LLP

Address Line 2: One International Place, Suite 2000

Address Line 4: Boston, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	216632-010201/US
NAME OF SUBMITTER:	Jennifer Kobrenski
SIGNATURE:	Jennifer Kobrenski
DATE SIGNED:	01/14/2025

Total Attachments: 37

source=Oxford_Inhibrx_Security#page1.tiff
source=Oxford_Inhibrx_Security#page2.tiff
source=Oxford_Inhibrx_Security#page3.tiff
source=Oxford_Inhibrx_Security#page4.tiff
source=Oxford_Inhibrx_Security#page5.tiff
source=Oxford_Inhibrx_Security#page6.tiff
source=Oxford_Inhibrx_Security#page7.tiff
source=Oxford_Inhibrx_Security#page8.tiff
source=Oxford_Inhibrx_Security#page9.tiff
source=Oxford_Inhibrx_Security#page10.tiff
source=Oxford_Inhibrx_Security#page11.tiff
source=Oxford_Inhibrx_Security#page12.tiff
source=Oxford_Inhibrx_Security#page13.tiff
source=Oxford_Inhibrx_Security#page14.tiff
source=Oxford_Inhibrx_Security#page15.tiff
source=Oxford_Inhibrx_Security#page16.tiff
source=Oxford_Inhibrx_Security#page17.tiff

source=Oxford_Inhibrx_Security#page18.tiff
source=Oxford_Inhibrx_Security#page19.tiff
source=Oxford_Inhibrx_Security#page20.tiff
source=Oxford_Inhibrx_Security#page21.tiff
source=Oxford_Inhibrx_Security#page22.tiff
source=Oxford_Inhibrx_Security#page23.tiff
source=Oxford_Inhibrx_Security#page24.tiff
source=Oxford_Inhibrx_Security#page25.tiff
source=Oxford_Inhibrx_Security#page26.tiff
source=Oxford_Inhibrx_Security#page27.tiff
source=Oxford_Inhibrx_Security#page28.tiff
source=Oxford_Inhibrx_Security#page29.tiff
source=Oxford_Inhibrx_Security#page30.tiff
source=Oxford_Inhibrx_Security#page31.tiff
source=Oxford_Inhibrx_Security#page32.tiff
source=Oxford_Inhibrx_Security#page33.tiff
source=Oxford_Inhibrx_Security#page34.tiff
source=Oxford_Inhibrx_Security#page35.tiff
source=Oxford_Inhibrx_Security#page36.tiff
source=Oxford_Inhibrx_Security#page37.tiff

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of January 13, 2025 by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”) for the benefit of the lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), and INHIBRX BIOSCIENCES, INC., a Delaware corporation (“**Grantor**”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement among Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, restated, amended and restated, modified or supplemented from time to time, the “**Loan Agreement**,” capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof. Notwithstanding the foregoing, such Collateral does not include any “intent to use” Trademarks.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

This Intellectual Property Security Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to its principles regarding conflicts of law.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

INHIBRX BIOSCIENCES, INC.

INHIBRX BIOSCIENCES, INC.
11025 North Torrey Pines Road
Suite 140
La Jolla, CA 92037
Attn: Mark Lappe, CEO

By: Kelly Deck
Name: KELLY DECK
Title: CFO

COLLATERAL AGENT:

Address of Lender:

OXFORD FINANCE LLC

115 South Union Street
Suite 300
Alexandria, VA 22314
Attn: Legal Department

By: _____
Name: _____
Title: _____

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

INHIBRX BIOSCIENCES, INC.
11025 North Torrey Pines Road
Suite 140
La Jolla, CA 92037
Attn: Mark Lappe, CEO

INHIBRX BIOSCIENCES, INC.

By: _____
Name: _____
Title: _____

COLLATERAL AGENT:

Address of Lender:

115 South Union Street
Suite 300
Alexandria, VA 22314
Attn: Legal Department

OXFORD FINANCE LLC

By:  _____
Name: Colette H. Featherly
Title: Senior Vice President

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None.

EXHIBIT B

Patents

[See attached.]

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
AU - Australia	2017207742	2017-01-11	2037-01-11	Issued	AU2017207742B2	2022-06-30	Multivalent and Multispecific 41BB-Binding Fusion Proteins
BR - Brazil	112018013677-8	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
CA - Canada	3009661	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
ID - Indonesia	P00201804675	2017-01-11	2037-01-11	Issued	IDP000089844	2023-10-03	Multivalent and Multispecific 41BB-Binding Fusion Proteins
IL - Israel	260530	2017-01-11	2037-01-11	Issued	IL260530	2023-12-02	Multivalent and Multispecific 41BB-Binding Fusion Proteins
JP - Japan	2018-535301	2017-01-11	2037-01-11	Issued	JP7022993B2	2022-02-10	Multivalent and Multispecific 41BB-Binding Fusion Proteins
KR - Korea, Republic of	10-2018-7022340	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
MX - Mexico	MX/A/2018/008308	2017-01-11	2037-01-11	Issued	MX414167	2024-06-20	Multivalent and Multispecific 41BB-Binding Fusion Proteins
NZ - New Zealand	743793	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
RU - Russia	2022127484	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
SG - Singapore	11201805532X	2017-01-11	2037-01-11	Issued	SG11201805532X	2023-12-25	Multivalent and Multispecific 41BB-Binding Fusion Proteins
US - United States	15/404016	2017-01-11	2037-08-14	Issued	US10501551B2	2019-12-10	Multivalent and Multispecific 41BB-Binding Fusion Proteins
US - United States	16/601825	2017-01-11	2037-05-04	Issued	US11566078	2023-01-31	PD1-Binding Proteins (as amended)
US - United States	18/067484	2017-01-11	2037-01-11	Issued [†]	US12187804	2025-01-07	PD1-Binding Proteins (as amended)
US - United States	18/956693	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific 41BB-Binding Fusion Proteins
ZA - South Africa	2022/11577	2017-01-11	2037-01-11	Allowed	ZA202211577B	2024-10-30	Multivalent and Multispecific 41BB-Binding Fusion Proteins
CA - Canada	3114693	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
CN - China	20198008077.1.7	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
EP - Europe	19794391.3	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
HK - Hong Kong	62022047379.2	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
JP - Japan	2021-520187	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
JP - Japan	2024-083758	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
TW - Taiwan	108136772	2019-10-09	2039-10-09	Allowed			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
TW - Taiwan	113140861	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
US - United States	17/283830	2019-10-09	2039-10-09	Pending			5T4 Single Domain Antibodies And Therapeutic Compositions Thereof
AU - Australia	2020269268	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
CA - Canada	3139061	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
CN - China	202080048186.1	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
EP - Europe	20726662.8	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
HK - Hong Kong	62022058060.4	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
JP - Japan	2021-564745	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
JP - Japan	2024-231707	2020-05-01	2040-05-01	Pending			CD123-Binding Polypeptides And Uses Thereof
US - United States	16/864478	2020-05-01	2040-12-24	Issued	US1434297	2022-09-06	CD123-Binding Polypeptides And Uses Thereof
US - United States	17/816540	2020-05-01	2040-05-01	Issued	US1191963	2024-03-05	CD123-Binding Polypeptides And Uses Thereof
CA - Canada	3168832	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof
CN - China	202180023573.4	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof
EP - Europe	21707540.7	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof
HK - Hong Kong	62023072503.3	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof
JP - Japan	2022-545975	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof
US - United States	17/795500	2021-01-28	2041-01-28	Pending			CD28 Single Domain Antibodies And Multivalent And Multispecific Constructs Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
AU - Australia	2018250641	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
BR - Brazil	112019020940-9	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
CA - Canada	3058477	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
CN - China	201880038526.5	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
EP - Europe	18721596.7	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
HK - Hong Kong	62020013353.1	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
HK - Hong Kong	62020013505.6	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
ID - Indonesia	P00201908881	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
IL - Israel	269826	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
IN - India	201917041454	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
JP - Japan	2019-555817	2018-04-11	2038-04-11	Issued	JP7164544	2022-10-24	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
JP - Japan	2022-168074	2018-04-11	2038-04-11	Issued	JP7450684	2024-03-07	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
JP - Japan	2024-032919	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
KR - Korea, Republic of	10-2019-7033354	2018-04-11	2038-04-11	Issued	MX418257	2024-10-31	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
KR - Korea, Republic of	10-2024-7038036	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
MX - Mexico	MX/A/2019/012198	2018-04-11	2038-04-11	Allowed			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
MX - Mexico	MX/a/2024/005371	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
MY - Malaysia	PI2019005867	2018-04-11	2038-04-11	Issued	MY-200973-A	2024-01-26	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
NZ - New Zealand	758264	2018-04-11	2038-04-11	Issued	NZ758264	2023-11-28	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
NZ - New Zealand	798584	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
PH - Philippines	12019502303	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
RU - Russia	2019135842	2018-04-11	2038-04-11	Issued	RU2813816	2024-02-19	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
RU - Russia	2023127070	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
SA - Saudi Arabia	519410284	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
SG - Singapore	11201909160W	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
TW - Taiwan	107112430	2018-04-11	2038-04-11	Allowed			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
US - United States	15/951137	2018-04-11	2038-04-24	Issued	US11866507	2024-01-09	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
US - United States	18/520308	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
ZA - South Africa	2019/06795	2018-04-11	2038-04-11	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Methods Of Using The Same
AU - Australia	2019251488	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
BR - Brazil	112020020604-0	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
BR - Brazil	BR122024001310-0	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
CA - Canada	3096123	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
CN - China	201980037529.1	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
EP - Europe	19719134.9	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
HK - Hong Kong	62021034946.5	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
IL - Israel	277863	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
IN - India	202017043715	2019-04-10	2039-04-10	Issued	IN541203	2024-06-10	Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
IN - India	202418036334	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
JP - Japan	2020-555516	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
KR - Korea, Republic of	10-2020-7032497	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
MX - Mexico	MX/A/2020/010638	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
NZ - New Zealand	768465	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
NZ - New Zealand	809720	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
NZ - New Zealand	809722	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
SA - Saudi Arabia	520420295	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
SA - Saudi Arabia	523441222	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
SG - Singapore	10202251485U	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
TW - Taiwan	108112538	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
US - United States	18/206354	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
ZA - South Africa	2020/06172	2019-04-10	2039-04-10	Pending			Multispecific Polypeptide Constructs Having Constrained CD3 Binding And Related Methods And Uses
CA - Canada	3105891	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
CN - China	201980061774.6	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
EP - Europe	19749970.0	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
HK - Hong Kong	62021042243.7	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
JP - Japan	2021-503831	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
TW - Taiwan	108126062	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
US - United States	16/520293	2019-07-23	2039-07-23	Allowed			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
US - United States	18/969,101	2019-07-23	2039-07-23	Pending			Multispecific Polypeptide Constructs Containing A Constrained CD3 Binding Domain And A Co-Stimulatory Receptor Binding Region And Methods Of Using The Same
AU - Australia	2020268827	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
BR - Brazil	112021021048-2	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
CA - Canada	3138969	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
CN - China	202080048688.4	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
EA - Eurasia validated in RU	202192997	2020-05-01	2040-05-01	Issued	EA046221	2024-02-16	CD33-Binding Polypeptides and Uses Thereof
EP - Europe	20730151.6	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
HK - Hong Kong	62022058061.2	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
ID - Indonesia	P00202108998	2020-05-01	2040-05-01	Issued	IDP000090304	2023-10-27	CD33-Binding Polypeptides and Uses Thereof
ID - Indonesia	P00202307875	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
IL - Israel	287782	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
IN - India	202117050146	2020-05-01	2040-05-01	Pending			CD33-binding polypeptides and uses thereof
JP - Japan	2021-564746	2020-05-01	2040-05-01	Issued	JP7525510	2024-07-22	CD33-Binding Polypeptides and Uses Thereof
JP - Japan	2024-114582	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
KR - Korea, Republic of	10-2021-7039701	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
MX - Mexico	MX/A/2021/013416	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
SG - Singapore	11202111711P	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
US - United States	16/864480	2020-05-01	2040-12-04	Issued	US11560428	2023-01-24	CD33-Binding Polypeptides and Uses Thereof
US - United States	18/067504	2020-05-01	2040-05-01	Issued	US12084502	2024-09-10	CD33-Binding Polypeptides and Uses Thereof
US - United States	18/792984	2020-05-01	2040-05-01	Pending			CD33-Binding Polypeptides and Uses Thereof
AU - Australia	2020268379	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
BR - Brazil	112021022356-8	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
CA - Canada	3139096	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
CN - China	202080048661.5	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
EA - Eurasia	202490156	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
EA - Eurasia validated in RU	202193072	2020-05-07	2040-05-07	Issued	EA046493	2024-03-21	CD33 Targeted Immunotherapies
EP - Europe	20802310.1	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
HK - Hong Kong	62022059634.5	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
ID - Indonesia	P00202109620	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
IL - Israel	287770	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
IN - India	202117052238	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
JP - Japan	2021--566152	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
KR - Korea, Republic of	10-2021-7040150	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
MX - Mexico	MX/A/2021/013591	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
SG - Singapore	10202204765Y	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
US - United States	17/608743	2020-05-07	2040-05-07	Pending			CD33 Targeted Immunotherapies
AU - Australia	2013217114	2013-02-06	2033-02-06	Issued	AU2013217114B2	2017-03-30	CD47 Antibodies and Methods of Use Thereof
CA - Canada	2863834	2013-02-06	2033-02-06	Issued	CA2863834	2024-09-20	CD47 Antibodies and Methods of Use Thereof
CL - Chile	201402086	2013-02-06	2033-02-06	Issued	CL60943B	2020-11-16	CD47 Antibodies and Methods of Use Thereof
CN - China	201380017900.0	2013-02-06	2033-02-06	Issued	ZL201380017900.0	2020-06-09	CD47 Antibodies and Methods of Use Thereof
CN - China	202010448862.1	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof
CO - Columbia	2014171778	2013-02-06	2033-02-06	Issued	CO14171778	2016-12-06	CD47 Antibodies and Methods of Use Thereof
CR - Costa Rica	201400406	2013-02-06	2033-02-06	Issued	CR4109	2021-08-10	CD47 Antibodies and Methods of Use Thereof
EA - Eurasia validated in RU	201400875	2013-02-06	2033-02-06	Issued	EA034778B1	2020-03-19	CD47 Antibodies and Methods of Use Thereof
EP - Europe	19173042.3	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
HK - Hong Kong	15105746.9	2013-02-06	2033-02-06	Issued	HK1205195	2020-06-19	CD47 Antibodies and Methods of Use Thereof
HK - Hong Kong	42020008954.8	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof
ID - Indonesia	P00201405270	2013-02-06	2033-02-06	Issued	IDP000058739B	2019-05-15	CD47 Antibodies and Methods of Use Thereof
IL - Israel	233934	2013-02-06	2033-02-06	Issued	IL233934B	2022-08-04	CD47 Antibodies and Methods of Use Thereof
IN - India	6438/CHE/NP/2014	2013-02-06	2033-02-06	Issued	IN395453B	2022-04-06	CD47 Antibodies and Methods of Use Thereof
JP - Japan	2014-556634	2013-02-06	2033-02-06	Issued	JP6273212B2	2018-01-31	CD47 Antibodies and Methods of Use Thereof
KR - Korea, Republic of	10-2014-7025286	2013-02-06	2033-02-06	Issued	KR102100388B1	2020-04-07	CD47 Antibodies and Methods of Use Thereof
KR - Korea, Republic of	10-2020-7009892	2013-02-06	2033-02-06	Issued	KR102338833B1	2021-12-13	CD47 Antibodies and Methods of Use Thereof
MX - Mexico	MX/A/2014/009427	2013-02-06	2033-02-06	Issued	MX360772B	2018-11-15	CD47 Antibodies and Methods of Use Thereof
MX - Mexico	MX/a/2018/003882	2013-02-06	2033-02-06	Issued	MX393557	2022-06-30	CD47 Antibodies and Methods of Use Thereof
MY - Malaysia	PI2014002294	2013-02-06	2033-02-06	Issued	MY169341A	2019-03-21	CD47 Antibodies and Methods of Use Thereof
NZ - New Zealand	628314	2013-02-06	2033-02-06	Issued	NZ628314B	2017-04-28	CD47 Antibodies and Methods of Use Thereof
PH - Philippines	12014501758	2013-02-06	2033-02-06	Issued	PH12014501758B1	2018-11-27	CD47 Antibodies and Methods of Use Thereof
SG - Singapore	10201700160R	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof
SG - Singapore	11201404638S	2013-02-06	2033-02-06	Issued	SG11201404638SB	2017-02-15	CD47 Antibodies and Methods of Use Thereof
TH - Thailand	1401004515	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof
UA - Ukraine	a 2014 09709	2013-02-06	2033-02-06	Issued	UA116772C2	2018-05-10	CD47 Antibodies and Methods of Use Thereof
US - United States	13/761087	2013-02-06	2033-02-06	Issued	US9045541B2	2015-06-02	CD47 Antibodies and Methods of Use Thereof
US - United States	14/700105	2013-02-06	2033-02-06	Issued	US9663575B2	2017-05-30	CD47 Antibodies and Methods of Use Thereof
VN - Vietnam	1201402973	2013-02-06	2033-02-06	Issued	VN10028772B	2021-07-26	CD47 Antibodies and Methods of Use Thereof
VN - Vietnam	1202103898	2013-02-06	2033-02-06	Pending			CD47 Antibodies and Methods of Use Thereof
ZA - South Africa	2014/05864	2013-02-06	2033-02-06	Issued	ZA201405864B	2015-11-25	CD47 Antibodies and Methods of Use Thereof
AU - Australia	2013377886	2013-08-06	2033-08-06	Issued	AU2013377886B2	2019-03-14	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
AU - Australia							
AU - Australia	2019200942	2013-08-06	2033-08-06	Issued	AU2019200942B2	2021-05-06	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
BR - Brazil	112015018851	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
CA - Canada	2900468	2013-08-06	2033-08-06	Issued	CA2900468	2024-04-30	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
CL - Chile	201502203	2013-08-06	2033-08-06	Issued	CL63005B	2021-09-27	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
CN - China	201380075409.3	2013-08-06	2033-08-06	Issued	ZL201380075409.3	2018-11-09	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
EA - Eurasia validated in RU	201500818	2013-08-06	2033-08-06	Issued	EA036963B1	2021-01-20	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
EP - Europe	22185286.6	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
EP - Europe validated in: DE, ES, FR, GB, IT	13874383.6	2013-08-06	2033-08-06	Issued	EP2953643B1	2023-02-22	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
HK - Hong Kong	161068857	2013-08-06	2033-08-06	Issued	HK1218863	2023-09-29	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
HK - Hong Kong	42023077677.5	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
ID - Indonesia	P00201505447	2013-08-06	2033-08-06	Issued	IDP000058855	2019-05-16	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
IL - Israel	240390	2013-08-06	2033-08-06	Issued	IL240390B	2020-09-01	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
IL - Israel	274566	2013-08-06	2033-08-06	Issued	IL274566B	2022-02-01	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
IN - India	4952/CHENP/2015	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
JP - Japan	2018-146460	2013-08-06	2033-08-06	Issued	JP6726238B2	2020-06-30	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
KR - Korea, Republic of	10-2015-7024103	2013-08-06	2033-08-06	Issued	KR102170196B1	2020-10-20	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
KR - Korea, Republic of	10-2020-7030070	2013-08-06	2033-08-06	Issued	KR102276974B1	2021-07-07	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
MO - Macao	1003573	2013-08-06	2033-08-06	Issued	MO//003573	2019-06-05	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
MX - Mexico	MX/a/2021/008851	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
NZ - New Zealand	710695	2013-08-06	2033-08-06	Issued	NZ710695B	2020-09-01	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
PE - Peru	2015001628	2013-08-06	2033-08-06	Issued	PE9897	2020-03-02	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
PH - Philippines	12015501729	2013-08-06	2033-08-06	Issued	PH12015501729B1	2021-07-29	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
SG - Singapore	10201706383X	2013-08-06	2033-08-06	Issued	SG10201706383X	2023-10-11	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
TH - Thailand	1501004422	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
US - United States	18/451025	2013-08-06	2033-08-06	Pending			Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
VN - Vietnam	1201503152	2013-08-06	2033-08-06	Issued	VN10029478B	2021-09-27	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
ZA - South Africa	2015/05745	2013-08-06	2033-08-06	Issued	ZA201505745B	2020-02-26	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
ZA - South Africa	2019/05292	2013-08-06	2033-08-06	Issued	ZA201905292B	2022-09-28	Non-Platelet Depleting And Non-Red Blood Cell Depleting CD47 Antibodies And Methods Of Use Thereof
CA - Canada	3225092	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
CN - China	2022800504720	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
EP - Europe	22754735.3	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
HK - Hong Kong	42024095877.7	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
JP - Japan	2024-503351	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
TW - Taiwan	111127060	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
US - United States	18/578133	2022-07-19	2042-07-19	Pending			CD8-Binding Polypeptides and Uses Thereof
TW - Taiwan	111127072	2022-07-19	2042-07-19	Pending			CD8-Targeted Modified IL-2 Polypeptides and Uses Thereof
US - United States	18/578137	2022-07-19	2042-07-19	Pending			CD8-Targeted Modified IL-2 Polypeptides and Uses Thereof
AU - Australia	2020267349	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
BR - Brazil	112021020999-9	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
CA - Canada	3138972	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
CN - China	202080048559.5	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
EA - Eurasia validated in RU	202192998	2020-05-01	2040-05-01	Issued	EA046257	2024-02-21	CLEC12a Binding Polypeptides and Uses Thereof
EP - Europe	20727504.1	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
HK - Hong Kong	62022058062.0	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
ID - Indonesia	P00202109000	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
IL - Israel	287781	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
IN - India	202117050659	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
JP - Japan	2021-564747	2020-05-01	2040-05-01	Issued	JP7571347	2024-10-15	CLEC12a Binding Polypeptides and Uses Thereof

PATENT

REEL: 069894 FRAME: 0066

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
JP - Japan	2024-140657	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
KR - Korea, Republic of	10-2021-7039702	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
MX - Mexico	MX/A/2021/013417	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
SG - Singapore	1120211731W	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
US - United States	16/864481	2020-05-01	2040-05-01	Issued	US12043667	2023-07-16	CLEC12a Binding Polypeptides and Uses Thereof
US - United States	18/748655	2020-05-01	2040-05-01	Pending			CLEC12a Binding Polypeptides and Uses Thereof
AU - Australia	2020267639	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
BR - Brazil	112021022365-7	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
CA - Canada	3148027	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
CN - China	202080049880.5	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
EA - Eurasia	202193071	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
EP - Europe	20801987.7	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
HK - Hong Kong	62022059633.7	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
ID - Indonesia	P00202109626	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
ID - Indonesia	P00202314491	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
IL - Israel	287769	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
IN - India	202117052262	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
JP - Japan	2021-566149	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
KR - Korea, Republic of	10-2021-7039632	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
MX - Mexico	MX/A/2021/013590	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
SG - Singapore	10202204769R	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
US - United States	17/608738	2020-05-07	2040-05-07	Pending			CLL-1 Targeted Immunotherapies
AU - Australia	2021266688	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
BR - Brazil	BR112022022352-8	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
CA - Canada	3177921	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
CN - China	202180045614.X	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
EA - Eurasia	202293166	2021-05-03	2041-05-03	Allowed			Canine PD-1-Binding Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
EP - Europe	21727700.3	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
IN - India	202217065168.0	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
JP - Japan	2022-567339	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
KR - Korea, Republic of	10-2022-7042086	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
MX - Mexico	MX/A/2022/013840	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
US - United States	17/922569	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
ZA - South Africa	2022/12718	2021-05-03	2041-05-03	Pending			Canine PD-1-Binding Polypeptides and Uses Thereof
CA - Canada	3115089	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
CN - China	201980082197.9	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
EP - Europe	19794390.5	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
HK - Hong Kong	62022047016.0	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
JP - Japan	2021-520217	2019-10-09	2039-10-09	Allowed			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
TW - Taiwan	108136743	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
US - United States	17/283903	2019-10-09	2039-10-09	Pending			DLL3 Single Domain Antibodies And Therapeutic Compositions Thereof
AU - Australia	20222291498	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
AU - Australia	2016291701	2016-07-18	2036-07-18	Issued	AU2016291701	2023-01-12	Multivalent And Multispecific DR5-Binding Fusion Proteins
BR - Brazil	112018000584-3	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
CA - Canada	2991634	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
CN - China	201680041274.2	2016-07-18	2036-07-18	Issued	ZL201680041274.2	2021-09-28	Multivalent And Multispecific DR5-Binding Fusion Proteins
CN - China	202111039963.9	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
EP - Europe	20189995.2	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
EP - Europe validated in: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR	16825315.1	2016-07-18	2036-07-18	Issued	EP3322734B1	2020-09-09	Multivalent And Multispecific DR5-Binding Fusion Proteins
HK - Hong Kong	18113517.7	2016-07-18	2036-07-18	Issued	HK1254433A1	2021-04-23	Multivalent And Multispecific DR5-Binding Fusion Proteins
HK - Hong Kong	42021038710.6	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
ID - Indonesia	P00201800330	2016-07-18	2036-07-18	Issued	IDP000075513	2021-03-15	Multivalent And Multispecific DR5-Binding Fusion Proteins
ID - Indonesia	P00202010721	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
IL - Israel	256772	2016-07-18	2036-07-18	Issued	IL256772	2022-08-02	Multivalent And Multispecific DR5-Binding Fusion Proteins
IL - Israel	307994	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
IN - India	201817001451	2016-07-18	2036-07-18	Issued	IN401979	2022-07-13	Multivalent And Multispecific DR5-Binding Fusion Proteins
IN - India	202118055765	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
JP - Japan	2018-501345	2016-07-18	2036-07-18	Issued	JP6807606B2	2020-12-10	Multivalent And Multispecific DR5-Binding Fusion Proteins

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
JP - Japan	2020-196358	2016-07-18	2036-07-18	Issued	JP7244938	2023-03-14	Multivalent And Multispecific DR5-Binding Fusion Proteins
JP - Japan	2022-191038	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
KR - Korea, Republic of	10-2018-7000975	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
MX - Mexico	MX/A/2018/000523	2016-07-18	2036-07-18	Issued	MX400419	2023-02-28	Multivalent And Multispecific DR5-Binding Fusion Proteins
MX - Mexico	MX/A/2023/002379	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
NZ - New Zealand	738850	2016-07-18	2036-07-18	Allowed			Multivalent And Multispecific DR5-Binding Fusion Proteins
NZ - New Zealand	777930	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
RU - Russia	2018102803	2016-07-18	2036-07-18	Issued	RU2748620C2	2021-05-28	Multivalent And Multispecific DR5-Binding Fusion Proteins
SG - Singapore	10201912410T	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
SG - Singapore	11201800223W	2016-07-18	2036-07-18	Issued	SG11201800223W	2020-08-24	Multivalent And Multispecific DR5-Binding Fusion Proteins
TH - Thailand	1801000218	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
US - United States	15/213296	2016-07-18	2036-07-18	Issued	US10308720	2019-06-04	Multivalent And Multispecific DR5-Binding Fusion Proteins
US - United States	16/387754	2016-07-18	2036-11-22	Issued	US11117973	2021-09-14	Multivalent And Multispecific DR5-Binding Fusion Proteins and Methods of Treating Neoplasms (as amended)
US - United States	17/394900	2016-07-18	#REF!	Issued	US11976126	2024-05-07	Multivalent And Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune Cells (as amended)
US - United States	18/626699	2016-07-18	2036-07-18	Pending			Multivalent And Multispecific DR5-Binding Fusion Proteins
ZA - South Africa	2018/00238	2016-07-18	2036-07-18	Issued	ZA201800238B	2021-07-28	Multivalent And Multispecific DR5-Binding Fusion Proteins
AU - Australia	2022223977	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
BR - Brazil	BR112023016264-5	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
CA - Canada	3208641	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
CN - China	202280015191.1	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
EP - Europe	22708678.2	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
HK - Hong Kong	62024089198.1	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
ID - Indonesia	P00202308179	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
IL - Israel	305265	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
IN - India	202317052010	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
JP - Japan	2023-549579	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
KR - Korea, Republic of	10-2023-7031673	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
MX - Mexico	MX/a/2023/009567	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
NZ - New Zealand	802253	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
RU - Russia	2023123641	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
SG - Singapore	11202305908P	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
TH - Thailand	2301004918	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
TW - Taiwan	111105924	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
US - United States	18/264475	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
ZA - South Africa	2023/07590	2022-02-18	2042-02-18	Pending			Formulations of DR5 Binding Proteins
AU - Australia	2023248848	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
BR - Brazil	BR112024020515-0	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
CA - Canada	3247628	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
CN - China	2023800426711	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
EA - Eurasia	202492583	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
EP - Europe	23720526.5	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
IL - Israel	316085	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
JP - Japan	2024-559130	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
KR - Korea, Republic of	10-2024-7037073	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
MX - Mexico	MX/a/2024/012300	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
NZ - New Zealand	815061	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
SG - Singapore	11202406845U	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
TW - Taiwan	112113053	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
US - United States	18/853278	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
ZA - South Africa	2024/07593	2023-04-07	2043-04-07	Pending			DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
AU - Australia	2023275703	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
BR - Brazil	BR112024023991-8	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
CA - Canada	3254393	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
CN - China	2023800417483	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
EA - Eurasia	202493035	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
EP - Europe	23731918.1	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
IL - Israel	317132	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
JP - Japan	to be assigned	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
KR - Korea, Republic of	to be assigned	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
MX - Mexico	MX/A/2024/014331	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
NZ - New Zealand	816113	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
SG - Singapore	11202407876Y	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
TW - Taiwan	112118932	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
US - United States	18/865,854	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
ZA - South Africa	2024/08876	2023-05-22	2043-05-22	Pending			DR5 Agonist and IAP Antagonist Combination Therapy
AU - Australia	2016209247	2016-01-21	2036-01-21	Issued	AU2016209247B2	2021-06-10	Non-immunogenic single domain antibodies
CA - Canada	2974192	2016-01-21	2036-01-21	Issued	CA2974192	2024-02-20	Non-immunogenic single domain antibodies
CA - Canada	3226056	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
CN - China	202210176367.3	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
EP - Europe	16740748.5	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
HK - Hong Kong	18106152.1	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
JP - Japan	2017-538374	2016-01-21	2036-01-21	Issued	JP7001474B2	2021-12-28	Non-immunogenic single domain antibodies
JP - Japan	2024-023504	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
US - United States	15/003234	2016-01-21	2036-02-07	Issued	US10526397B2	2020-01-07	Non-immunogenic single domain antibodies
US - United States	18/807532	2016-01-21	2036-01-21	Pending			Non-immunogenic single domain antibodies
AU - Australia	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
CA - Canada	3258646	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
CN - China	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
EP - Europe	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
IL - Israel	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
JP - Japan	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
MX - Mexico	MX/a/2024/015167	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
NZ - New Zealand	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
SG - Singapore	11202408595Y	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
TW - Taiwan	112121593	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
US - United States	18/871,526	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
ZA - South Africa	to be assigned	2023-06-09	2043-06-09	Pending			FcRn-Binding Polypeptides and Uses Thereof
US - United States	15/217754	2016-07-22	2036-07-22	Issued	US10093742B2	2018-10-09	Multivalent And Multispecific G1TR-Binding Fusion Proteins

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
CA - Canada	3251817	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
CN - China	2023800379937	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
EP - Europe	23728551.5	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
JP - Japan	to be assigned	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
TW - Taiwan	112116551	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
US - United States	18/861746	2023-05-04	2043-05-04	Pending			Albumin-Binding Polypeptides and Uses Thereof
AR - Argentina	P240101834	2024-07-12	2044-07-12	Pending			IgE Binding Polypeptides and Uses Thereof
TW - Taiwan	113126447	2024-07-15	2044-07-15	Pending			IgE Binding Polypeptides and Uses Thereof
US - United States	18/792921	2024-07-12	2044-07-12	Pending			IgE Binding Polypeptides and Uses Thereof
WO - WIPO (National Stage Entry 30 month deadline 2026-01-12)	PCT/US24/037846	2024-07-12		Pending			IgE Binding Polypeptides and Uses Thereof
AR - Argentina	P20200100028	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
AU - Australia	2020206672	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
BR - Brazil	112021012294-0	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CA - Canada	3125529	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CL - Chile	202101779	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CN - China	202080018011.6	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
EP - Europe	20702547.9	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
GC - Gulf Cooperation Council	2020-38967	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
GC - Gulf Cooperation Council	2022-41676	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
HK - Hong Kong	62022050867.0	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
IL - Israel	284633	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
IN - India	202117028056	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
JP - Japan	2021-538982	2020-01-06	2040-01-06	Issued	JP7594161	2024-11-26	Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
JP - Japan	2024-185692	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
KR - Korea, Republic of	10-2021-7024431	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
MX - Mexico	MX/A/2021/008147	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
MY - Malaysia	PI2021003501	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
NZ - New Zealand	777431	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
NZ - New Zealand	to be assigned	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
NZ - New Zealand	to be assigned	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
RU - Russia	2021123226	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
SG - Singapore	11202106700W	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
TW - Taiwan	109100336	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
US - United States	17/418458	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
ZA - South Africa	2021/04475	2020-01-06	2040-01-06	Pending			Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
AR - Argentina	P210101857	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
AU - Australia	2021299552	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
CA - Canada	3184618	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
CN - China	202180053315.0	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
EP - Europe	21748720.6	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
HK - Hong Kong	62023073092.6	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
IL - Israel	299542	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
IN - India	202317006269	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
JP - Japan	2022-580769	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
KR - Korea, Republic of	10-2023-7003798	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
MX - Mexico	MX/a/2022/016532	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
NZ - New Zealand	795669	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
SG - Singapore	11202261484T	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
TW - Taiwan	110124255	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
US - United States	18/002613	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
ZA - South Africa	2022/13882	2021-07-01	2041-07-01	Pending			Polypeptides Comprising Modified IL-2 Polypeptides And Uses Thereof
CA - Canada	3228815	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
CN - China	2022800588266	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
EP - Europe	22798405.1	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
HK - Hong Kong	62024097911.7	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
JP - Japan	2024-512984	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
TW - Taiwan	111132424	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
US - United States	18/685665	2022-08-29	2042-08-29	Pending			NKp46-Binding Polypeptides and Uses Thereof
TW - Taiwan	111132425	2021-08-30	2041-08-30	Pending			NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
US - United States	18/685666	2021-08-29	2041-08-29	Pending			NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
AU - Australia	2017207318	2017-01-11	2037-01-11	Issued	AU2017207318	2024-03-21	Multivalent and Multispecific OX40-Binding Fusion Proteins
AU - Australia	2024200551	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
BR - Brazil	112018013911-4	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
CA - Canada	3009075	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
CN - China	201780005939.9	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
EP - Europe	17738885.7	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
HK - Hong Kong	19121596.1	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
ID - Indonesia	P00201804576	2017-01-11	2037-01-11	Issued	IDP000085528	2023-02-07	Multivalent and Multispecific OX40-Binding Fusion Proteins
ID - Indonesia	P00202106690	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
IL - Israel	260531	2017-01-11	2037-01-11	Issued	IL260531	2023-04-03	Multivalent and Multispecific OX40-Binding Fusion Proteins
IL - Israel	298686	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
JP - Japan	2018-535298	2017-01-11	2037-01-11	Issued	JP7328761	2023-08-08	Multivalent and Multispecific OX40-Binding Fusion Proteins
JP - Japan	2022-154355	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
KR - Korea, Republic of	10-2018-7022337	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
MX - Mexico	MX/A/2018/008310	2017-01-11	2037-01-11	Issued	MX413825	2024-06-11	Multivalent and Multispecific OX40-Binding Fusion Proteins
MX - Mexico	MX/a/2024/004017	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
NZ - New Zealand	743731	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
NZ - New Zealand	783287	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
RU - Russia	2018128629	2017-01-11	2037-01-11	Issued	RU2773052	2022-05-30	Multivalent and Multispecific OX40-Binding Fusion Proteins
RU - Russia	2022106508	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
SG - Singapore	10202303481W	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
SG - Singapore	11201805422W	2017-01-11	2037-01-11	Issued	SG11201805422W	2024-01-10	Multivalent and Multispecific OX40-Binding Fusion Proteins
TH - Thailand	1801004046	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
US - United States	16/295332	2017-01-11	2037-05-04	Issued	US11117972	2021-09-14	Multivalent and Multispecific OX40-Binding Fusion Proteins
US - United States	17/398851	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
ZA - South Africa	2018/04103	2017-01-11	2037-01-11	Pending			Multivalent and Multispecific OX40-Binding Fusion Proteins
AR - Argentina	P20190102293	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
AU - Australia	2019321490	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
BR - Brazil	112021002164-7	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
CA - Canada	3107767	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
CL - Chile	202100347	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
CN - China	201980054189.3	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
EP - Europe	19762513.0	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
GC - Gulf Cooperation Council	2019-38123	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
HK - Hong Kong	62021039061.8	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
HK - Hong Kong	62021039127.7	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
ID - Indonesia	P00202101153	2019-08-12	2039-08-12	Issued	IDP000091386	2024-01-03	OX40-Binding Polypeptides And Uses Thereof
ID - Indonesia	P00202306369	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
IL - Israel	280808	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
IN - India	202117006098	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
JP - Japan	2021-506977	2019-08-12	2039-08-12	Issued	JP7462611	2024-03-28	OX40-Binding Polypeptides And Uses Thereof
JP - Japan	2024-048858	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
KR - Korea, Republic of	10-2021-7006759	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
MX - Mexico	MX/A/2021/001703	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
MY - Malaysia	PI2021000597	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
NZ - New Zealand	772290	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
NZ - New Zealand	813168	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
PH - Philippines	12021550289	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
RU - Russia	2021106197	2019-08-12	2039-08-12	Issued	RU2802070	2023-08-22	OX40-Binding Polypeptides And Uses Thereof
SG - Singapore	11202101173T	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
TH - Thailand	2101000677	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
TW - Taiwan	108128661	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
US - United States	16/538216	2019-08-12	2040-02-08	Issued	US11447556	2022-09-22	OX40-Binding Polypeptides And Uses Thereof
US - United States	17/818106	2019-08-12	2039-08-12	Issued	US12012459	2024-06-18	OX40-Binding Polypeptides And Uses Thereof
US - United States	18/658421	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
VN - Vietnam	1202101221	2019-08-12	2039-08-12	Allowed			OX40-Binding Polypeptides And Uses Thereof
ZA - South Africa	2021/00634	2019-08-12	2039-08-12	Pending			OX40-Binding Polypeptides And Uses Thereof
WO - W/PO (National Stage Entry 30 month deadline 2026-03-01)	PCT/US23/73279	2023-09-01		Pending			OX40 Agonist Therapy
WO - W/PO (National Stage Entry 30 month deadline 2026-03-01)	PCT/US24/16505	2024-02-20		Pending			OX40 Agonist Therapy
AU - Australia	2019356573	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
CA - Canada	3115285	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
CN - China	201980082154.0	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
EP - Europe	19797897.6	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
GC - Gulf Cooperation Council	2019-41515	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
HK - Hong Kong	62022048142.3	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
JP - Japan	2021-519705	2019-10-11	2039-10-11	Issued	JP7453219	2024-03-11	PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
JP - Japan	2023-222989	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
TW - Taiwan	108136936	2019-10-14	2039-10-14	Issued	TW/856030	2024-09-21	PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
TW - Taiwan	113129716	2019-10-14	2039-10-14	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
US - United States	16/600298	2019-10-11	2039-10-11	Issued	US11208485B2	2021-12-28	PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
US - United States	17/524016	2019-10-11	2039-10-11	Issued	US11945869	2024-04-02	PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
US - United States	18/589,536	2019-10-11	2039-10-11	Pending			PD-1 Single Domain Antibodies And Therapeutic Compositions Thereof
AR - Argentina	P230100976	2023-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
AU - Australia		2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
BR - Brazil	1120240217744	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
CA - Canada	3248575	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
CL - Chile	202403189	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
CN - China	202380035456.9	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
CO - Columbia	NC2024/0015409	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
EA - Eurasia	202492731	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
EP - Europe	23792825.4	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
ID - Indonesia	P00202413432	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
IL - Israel	316176	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
IN - India	202447089501	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
JP - Japan	2024-562791	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry ¹	Status	Patent No.	Issue Date	Title
KR - Korea, Republic of	10-2024-7036655	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
MX - Mexico	MX/a/2024/012999	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
MY - Malaysia	PI2024006058	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
NZ - New Zealand	816401	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
PE - Peru	2293-2024	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
PH - Philippines	1-2024-552522	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
SG - Singapore	11202407324W	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
TW - Taiwan	112115219	2023-04-24	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
US - United States	18/923531	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
ZA - South Africa	2024/07533	2024-04-21	2043-04-21	Pending			Siglec8 Binding Polypeptides and Uses Thereof
AU - Australia	2023205911	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
BR - Brazil	BR112024013518-7	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
CA - Canada	3242658	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
CN - China	2023800160826	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
EP - Europe	23704000.1	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
HK - Hong Kong	62024099654	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
IL - Israel	314073	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
IN - India	202417057764	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
JP - Japan	2024-540715	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
KR - Korea, Republic of	10-2024-7026008	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
MX - Mexico	MX/a/2024/008389	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
NZ - New Zealand	812516	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof

2025 Inhibrx Biosciences Patent Portfolio

Country	App No.	Effective Filing Date	Expected Expiry [^]	Status	Patent No.	Issue Date	Title
RU - Russia	2024121933	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
SG - Singapore	11202404580S	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
TW - Taiwan	112100154	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
US - United States	18/726347	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
ZA - South Africa	2024/05240	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Binding Polypeptides and Uses Thereof
TW - Taiwan	112100153	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
US - United States	18/726350	2023-01-04	2043-01-04	Pending			Gamma Delta T Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
US - United States	15/144470	2016-05-02	2036-05-02	Issued***	US10344078B2	2019-07-09	Type III Secretion System Targeting Molecules
US - United States	16/419677	2016-05-02	2036-05-02	Issued***	US10745466B2	2020-08-18	Type III Secretion System Targeting Molecules
US - United States	16/119950	2016-07-22	2036-07-22	Issued***	US10844129B2	2020-11-24	Multivalent And Multispecific G1TR-Binding Fusion Proteins
US - United States	17/283902	2019-10-09	2039-10-09	Pending***			B7H3 Single Domain Antibodies And Therapeutic Compositions Thereof

[^]includes applicable PTA for US cases

#status/information updated to reflect recent grant

*** planning to allow application/patent to lapse

EXHIBIT C

Trademarks

[See attached.]

INTELEX

Mark	Country	App No.	Filing Date	Status	Reg No.	Reg. Date	Class
INHIBRX	US - United States	85321519	2011-05-16	Registered	4083111	2012-01-10	042 - research and development of therapeutic antibodies
CONTRA-MAB	CN - China	37763803	2019-04-24	Registered	37763803	2020-02-28	005 - engineered proteins...
CONTRA-MAB	US - United States	88081271	2018-08-16	Registered	6029997	2020-04-07	005 - engineered proteins...
INHIBRX	US - United States	88595545	2019-08-28	Registered	6018399	2020-03-24	042 - research and development of therapeutic antibodies
	US - United States	97/673066	2022-11-11	Allowed			042 - research and development of therapeutic antibodies
	CA - Canada	1721813	2023-03-02	Pending			005 - pharmaceutical, cancer
	CH - Switzerland	1721813	2023-03-02	Registered	1721813	2024-02-20	005 - pharmaceutical, cancer
	CN - China	1721813	2023-03-02	Registered	97794001	2023-12-04	005 - pharmaceutical, cancer
INETDRIVOKE	GB - Great Britain	1721813	2023-03-02	Registered	WO0000001721813	2023-06-20	005 - pharmaceutical, cancer
INETDRIVOKE	WO - WIPO	1721813	2023-03-02	Pending			005 - pharmaceutical, cancer
INETDRIVOKE	KR - Korea, Republic of	1721813	2023-03-02	Registered	1721813	2024-08-07	005 - pharmaceutical, cancer
INETDRIVOKE	NO - Norway	1721813	2023-03-02	Registered	1721813	2024-03-19	005 - pharmaceutical, cancer
INETDRIVOKE	TR - Turkey	1721813	2023-03-02	Registered	1721813	2023-11-06	005 - pharmaceutical, cancer
INETDRIVOKE	EP - Europe	018836950	2023-02-16	Registered	18836950	2023-06-07	005 - pharmaceutical, cancer
INETDRIVOKE	JP - Japan	2023-15726	2023-02-16	Registered	6719617	2023-07-21	005 - pharmaceutical, cancer
INETDRIVOKE	US - United States	97/794001	2023-02-14	Allowed			005 - pharmaceutical, cancer
ZETTERAQ	CA - Canada	1721590	2023-03-02	Pending			005 - pharmaceutical, cancer
ZETTERAQ	CH - Switzerland	1721590	2023-03-02	Registered	1721590	2024-02-15	005 - pharmaceutical, cancer
ZETTERAQ	CN - China	1721590	2023-03-02	Registered	97793994	2023-12-04	005 - pharmaceutical, cancer
ZETTERAQ	GB - Great Britain	1721590	2023-03-02	Registered	WO0000001721590	2023-06-20	005 - pharmaceutical, cancer
ZETTERAQ	WO - WIPO	1721590	2023-03-02	Pending			005 - pharmaceutical, cancer
ZETTERAQ	KR - Korea, Republic of	1721590	2023-03-02	Registered	1721590	7/11/2024	005 - pharmaceutical, cancer
ZETTERAQ	NO - Norway	1721590	2023-03-02	Registered	1721590	2024-03-19	005 - pharmaceutical, cancer
ZETTERAQ	TR - Turkey	1721590	2023-03-02	Registered	1721590	2023-11-06	005 - pharmaceutical, cancer
ZETTERAQ	EP - Europe	018837042	2023-02-16	Registered	18837042	2023-06-07	005 - pharmaceutical, cancer
ZETTERAQ	JP - Japan	2023-15725	2023-02-16	Registered	6719616	2023-07-21	005 - pharmaceutical, cancer
ZETTERAQ	US - United States	97/793994	2023-02-14	Allowed			005 - pharmaceutical, cancer

2025 Inhibrx Biosciences TM Portfolio

Mark	Country	App No.	Filing Date	Status	Reg No.	Reg. Date	Class
OZEDRIVY	CA - Canada	1721809	2023-03-02	Pending			005 - pharmaceutical, cancer
OZEDRIVY	CH - Switzerland	1721809	2023-03-02	Registered	1721809	2024-02-15	005 - pharmaceutical, cancer
OZEDRIVY	CN - China	1721809	2023-03-02	Registered	97793983	2023-12-04	005 - pharmaceutical, cancer
OZEDRIVY	GB - Great Britain	1721809	2023-03-02	Registered	WO0000001721809	2023-06-20	005 - pharmaceutical, cancer
OZEDRIVY	WO - WIPO	1721809	2023-03-02	Pending			005 - pharmaceutical, cancer
OZEDRIVY	KR - Korea, Republic of	1721809	2023-03-02	Registered	1721809	2024-08-07	005 - pharmaceutical, cancer
OZEDRIVY	NO - Norway	1721809	2023-03-02	Registered	1721809	2024-03-19	005 - pharmaceutical, cancer
OZEDRIVY	TR - Turkey	1721809	2023-03-02	Registered	1721809	2023-11-06	005 - pharmaceutical, cancer
OZEDRIVY	EP - Europe	018837043	2023-02-16	Registered	18837043	2023-06-07	005 - pharmaceutical, cancer
OZEDRIVY	JP - Japan	2023-15724	2023-02-16	Registered	6719615	2023-07-21	005 - pharmaceutical, cancer
OZEDRIVY	US - United States	97/793983	2023-02-14	Allowed			005 - pharmaceutical, cancer
INHIBRX BIOSCIENCES	US - United States	98/440219	2024-03-08	Pending			005 - pharmaceutical, cancer
INHIBRX BIOSCIENCES	US - United States	98/440190	2024-03-08	Pending			042 - research and development of therapeutic antibodies

PATENT**REEL: 069894 FRAME: 0085****RECORDED: 01/14/2025**